rubitecan has been researched along with Colorectal Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Auber, M; Cai, C; Kiefer, G; Matin, K; Patel, H; Potter, D; Ramanathan, RK; Schmotzer, A; Stoller, R; Zamboni, W | 1 |
| Adank, S; Beijnen, JH; Botma, HJ; Ganser, A; Herr, A; Rosing, H; Schöffski, P; Van den Brande, J; Vermorken, JB; Volk, J; Wanders, J | 1 |
2 trial(s) available for rubitecan and Colorectal Cancer
| Article | Year |
|---|---|
Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Male; Middle Aged; Survival Analysis; Treatment Failure; Treatment Outcome | 2006 |
Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer-significant effect of food intake on the bioavailability of the oral camptothecin analogue.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biological Availability; Camptothecin; Colorectal Neoplasms; Cross-Over Studies; Eating; Female; Humans; Male; Middle Aged; Neoplasm Metastasis | 2002 |